rewirebio.iobenchmarks
Evidence and investigation

Contested results

Where one study disagrees with what other studies report for the same models, and what we are doing to resolve each case.

These are automatic leads, not findings of error. Each release, a check compares how every study ranks the models it shares with other studies. It flags a study that reverses the order the others agree on, or whose gap to a shared reference model lies well outside theirs. Different tasks, populations or metrics often explain a flag.

A flag never hides a result. Flagged results stay in every table, page and download, marked Contested. A result is withheld only when a reviewer marks it disputed.

How the check works, and how each follow-up is recorded: discrepancies between studies.

In this release

  • 192open
  • 6settled
  • 7resolved
  • 3medium severity
  • 202low severity

Release 2026-11-21-c8bea25e5abb · 205 findings in all · rules version 5

Findings

Status: All · Open · Settled · Resolved

Severity: All · Medium · Low

State: All · Not yet reviewed · Under investigation · Explained · Confirmed error · Not a real disagreement

Showing findings that compare MutFormer. All models

21 findings match, most severe first.

DEOGEN2 and MutFormer: Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) and An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers disagree

  • Low severity
  • Not yet reviewed
  • Two-study conflict
  • unknown

Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) ranks MutFormer above DEOGEN2 in 7 of 7 comparisons; An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers ranks DEOGEN2 above MutFormer in 6 of 6 comparisons. No other study gives a verdict, so neither is the outlier.

2 papers rank DEOGEN2 above MutFormer in 6 of their 13 comparisons and MutFormer higher in 7. Of those papers, Livesey and Marsh 2025 ranks MutFormer higher on its own (7 of 7).

Comparisons in which each paper scores DEOGEN2 or MutFormer higher2 other papers: DEOGEN2 higher in 6, MutFormer higher in 7, 0 ties.2 other papers6 DEOGEN2 higher67 MutFormer higher7
DEOGEN2 higherTieMutFormer higher
Compared
DEOGEN2, MutFormer

Not reviewed yet.

MPC and MutFormer: Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) and An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers disagree

  • Low severity
  • Not yet reviewed
  • Two-study conflict
  • unknown

Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) ranks MutFormer above MPC in 7 of 7 comparisons; An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers ranks MPC above MutFormer in 6 of 6 comparisons. No other study gives a verdict, so neither is the outlier.

2 papers rank MPC above MutFormer in 6 of their 13 comparisons and MutFormer higher in 7. Of those papers, Livesey and Marsh 2025 ranks MutFormer higher on its own (7 of 7).

Comparisons in which each paper scores MPC or MutFormer higher2 other papers: MPC higher in 6, MutFormer higher in 7, 0 ties.2 other papers6 MPC higher67 MutFormer higher7
MPC higherTieMutFormer higher
Compared
MPC, MutFormer

Not reviewed yet.

MutFormer and SIFT: Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) and An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers disagree

  • Low severity
  • Not yet reviewed
  • Two-study conflict
  • unknown

Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) ranks MutFormer above SIFT in 7 of 7 comparisons; An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers ranks SIFT above MutFormer in 3 of 4 comparisons. No other study gives a verdict, so neither is the outlier.

2 papers rank MutFormer above SIFT in 8 of their 13 comparisons and SIFT higher in 3; 2 are ties. Of those papers, An openly licensed benchmark… ranks SIFT higher on its own (3 of 6).

Comparisons in which each paper scores MutFormer or SIFT higher2 other papers: MutFormer higher in 8, SIFT higher in 3, 2 ties.2 other papers8 MutFormer higher82 tie23 SIFT higher3
MutFormer higherTieSIFT higher
Compared
MutFormer, SIFT

Not reviewed yet.

MutFormer and PolyPhen-2: Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) and An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers disagree

  • Low severity
  • Not yet reviewed
  • Two-study conflict
  • unknown

Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) ranks MutFormer above PolyPhen-2 in 6 of 6 comparisons; An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers ranks PolyPhen-2 above MutFormer in 5 of 6 comparisons. No other study gives a verdict, so neither is the outlier.

2 papers rank MutFormer above PolyPhen-2 in 7 of their 12 comparisons and PolyPhen-2 higher in 5. Of those papers, An openly licensed benchmark… ranks PolyPhen-2 higher on its own (5 of 6).

Comparisons in which each paper scores MutFormer or PolyPhen-2 higher2 other papers: MutFormer higher in 7, PolyPhen-2 higher in 5, 0 ties.2 other papers7 MutFormer higher75 PolyPhen-2 higher5
MutFormer higherTiePolyPhen-2 higher
Compared
MutFormer, PolyPhen-2

Not reviewed yet.

MutFormer and REVEL: Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) and An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers disagree

  • Low severity
  • Not yet reviewed
  • Two-study conflict
  • unknown

Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) ranks MutFormer above REVEL in 6 of 7 comparisons; An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers ranks REVEL above MutFormer in 6 of 6 comparisons. No other study gives a verdict, so neither is the outlier.

2 papers rank MutFormer above REVEL in 6 of their 13 comparisons and REVEL higher in 7. Of those papers, An openly licensed benchmark… ranks REVEL higher on its own (6 of 6).

Comparisons in which each paper scores MutFormer or REVEL higher2 other papers: MutFormer higher in 6, REVEL higher in 7, 0 ties.2 other papers6 MutFormer higher67 REVEL higher7
MutFormer higherTieREVEL higher
Compared
MutFormer, REVEL

Not reviewed yet.

MutFormer and PROVEAN: Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) and An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers disagree

  • Low severity
  • Not yet reviewed
  • Two-study conflict
  • unknown

Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) ranks MutFormer above PROVEAN in 7 of 7 comparisons; An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers ranks PROVEAN above MutFormer in 6 of 6 comparisons. No other study gives a verdict, so neither is the outlier.

2 papers rank MutFormer above PROVEAN in 7 of their 13 comparisons and PROVEAN higher in 6. Of those papers, An openly licensed benchmark… ranks PROVEAN higher on its own (6 of 6).

Comparisons in which each paper scores MutFormer or PROVEAN higher2 other papers: MutFormer higher in 7, PROVEAN higher in 6, 0 ties.2 other papers7 MutFormer higher76 PROVEAN higher6
MutFormer higherTiePROVEAN higher
Compared
MutFormer, PROVEAN

Not reviewed yet.

MutFormer and ESM-1b: Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) and An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers disagree

  • Low severity
  • Not yet reviewed
  • Two-study conflict
  • unknown

Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) ranks MutFormer above ESM-1b in 7 of 7 comparisons; An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers ranks ESM-1b above MutFormer in 6 of 6 comparisons. No other study gives a verdict, so neither is the outlier.

2 papers rank MutFormer above ESM-1b in 7 of their 13 comparisons and ESM-1b higher in 6. Of those papers, An openly licensed benchmark… ranks ESM-1b higher on its own (6 of 6).

Comparisons in which each paper scores MutFormer or ESM-1b higher2 other papers: MutFormer higher in 7, ESM-1b higher in 6, 0 ties.2 other papers7 MutFormer higher76 ESM-1b higher6
MutFormer higherTieESM-1b higher
Compared
MutFormer, ESM-1b

Not reviewed yet.

M-CAP and MutFormer: Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) and An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers disagree

  • Low severity
  • Not yet reviewed
  • Two-study conflict
  • unknown

Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) ranks MutFormer above M-CAP in 7 of 7 comparisons; An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers ranks M-CAP above MutFormer in 4 of 5 comparisons. No other study gives a verdict, so neither is the outlier.

2 papers rank M-CAP above MutFormer in 4 of their 13 comparisons and MutFormer higher in 8; 1 is a tie. Of those papers, Livesey and Marsh 2025 ranks MutFormer higher on its own (7 of 7).

Comparisons in which each paper scores M-CAP or MutFormer higher2 other papers: M-CAP higher in 4, MutFormer higher in 8, 1 tie.2 other papers4 M-CAP higher41 tie8 MutFormer higher8
M-CAP higherTieMutFormer higher
Compared
M-CAP, MutFormer

Not reviewed yet.

FATHMM-XF and MutFormer: Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) and An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers disagree

  • Low severity
  • Not yet reviewed
  • Two-study conflict
  • unknown

Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) ranks MutFormer above FATHMM-XF in 7 of 7 comparisons; An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers ranks FATHMM-XF above MutFormer in 6 of 6 comparisons. No other study gives a verdict, so neither is the outlier.

2 papers rank FATHMM-XF above MutFormer in 6 of their 13 comparisons and MutFormer higher in 7. Of those papers, Livesey and Marsh 2025 ranks MutFormer higher on its own (7 of 7).

Comparisons in which each paper scores FATHMM-XF or MutFormer higher2 other papers: FATHMM-XF higher in 6, MutFormer higher in 7, 0 ties.2 other papers6 FATHMM-XF higher67 MutFormer higher7
FATHMM-XF higherTieMutFormer higher
Compared
FATHMM-XF, MutFormer

Not reviewed yet.

MutFormer and BayesDel: Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) and An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers disagree

  • Low severity
  • Not yet reviewed
  • Two-study conflict
  • unknown

Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) ranks MutFormer above BayesDel in 6 of 7 comparisons; An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers ranks BayesDel above MutFormer in 6 of 6 comparisons. No other study gives a verdict, so neither is the outlier.

2 papers rank MutFormer above BayesDel in 6 of their 13 comparisons and BayesDel higher in 7. Of those papers, An openly licensed benchmark… ranks BayesDel higher on its own (6 of 6).

Comparisons in which each paper scores MutFormer or BayesDel higher2 other papers: MutFormer higher in 6, BayesDel higher in 7, 0 ties.2 other papers6 MutFormer higher67 BayesDel higher7
MutFormer higherTieBayesDel higher
Compared
MutFormer, BayesDel

Not reviewed yet.

MutFormer and MVP: Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) and An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers disagree

  • Low severity
  • Not yet reviewed
  • Two-study conflict
  • unknown

Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) ranks MutFormer above MVP in 7 of 7 comparisons; An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers ranks MVP above MutFormer in 6 of 6 comparisons. No other study gives a verdict, so neither is the outlier.

2 papers rank MutFormer above MVP in 7 of their 13 comparisons and MVP higher in 6. Of those papers, An openly licensed benchmark… ranks MVP higher on its own (6 of 6).

Comparisons in which each paper scores MutFormer or MVP higher2 other papers: MutFormer higher in 7, MVP higher in 6, 0 ties.2 other papers7 MutFormer higher76 MVP higher6
MutFormer higherTieMVP higher
Compared
MutFormer, MVP

Not reviewed yet.

ClinPred and MutFormer: Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) and An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers disagree

  • Low severity
  • Not yet reviewed
  • Two-study conflict
  • unknown

Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) ranks MutFormer above ClinPred in 7 of 7 comparisons; An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers ranks ClinPred above MutFormer in 6 of 6 comparisons. No other study gives a verdict, so neither is the outlier.

2 papers rank ClinPred above MutFormer in 6 of their 13 comparisons and MutFormer higher in 7. Of those papers, Livesey and Marsh 2025 ranks MutFormer higher on its own (7 of 7).

Comparisons in which each paper scores ClinPred or MutFormer higher2 other papers: ClinPred higher in 6, MutFormer higher in 7, 0 ties.2 other papers6 ClinPred higher67 MutFormer higher7
ClinPred higherTieMutFormer higher
Compared
ClinPred, MutFormer

Not reviewed yet.

MutationAssessor and MutFormer: Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) and An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers disagree

  • Low severity
  • Not yet reviewed
  • Two-study conflict
  • unknown

Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) ranks MutFormer above MutationAssessor in 7 of 7 comparisons; An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers ranks MutationAssessor above MutFormer in 5 of 5 comparisons. No other study gives a verdict, so neither is the outlier.

2 papers rank MutationAssessor above MutFormer in 5 of their 13 comparisons and MutFormer higher in 7; 1 is a tie. Of those papers, Livesey and Marsh 2025 ranks MutFormer higher on its own (7 of 7).

Comparisons in which each paper scores MutationAssessor or MutFormer higher2 other papers: MutationAssessor higher in 5, MutFormer higher in 7, 1 tie.2 other papers5 MutationAssessor higher51 tie7 MutFormer higher7
MutationAssessor higherTieMutFormer higher
Compared
MutationAssessor, MutFormer

Not reviewed yet.

MetaSVM and MutFormer: Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) and An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers disagree

  • Low severity
  • Not yet reviewed
  • Two-study conflict
  • unknown

Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) ranks MutFormer above MetaSVM in 7 of 7 comparisons; An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers ranks MetaSVM above MutFormer in 4 of 5 comparisons. No other study gives a verdict, so neither is the outlier.

2 papers rank MetaSVM above MutFormer in 4 of their 13 comparisons and MutFormer higher in 8; 1 is a tie. Of those papers, Livesey and Marsh 2025 ranks MutFormer higher on its own (7 of 7).

Comparisons in which each paper scores MetaSVM or MutFormer higher2 other papers: MetaSVM higher in 4, MutFormer higher in 8, 1 tie.2 other papers4 MetaSVM higher41 tie8 MutFormer higher8
MetaSVM higherTieMutFormer higher
Compared
MetaSVM, MutFormer

Not reviewed yet.

MutFormer and MutPred: Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) and An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers disagree

  • Low severity
  • Not yet reviewed
  • Two-study conflict
  • unknown

Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) ranks MutFormer above MutPred in 6 of 7 comparisons; An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers ranks MutPred above MutFormer in 6 of 6 comparisons. No other study gives a verdict, so neither is the outlier.

2 papers rank MutFormer above MutPred in 6 of their 13 comparisons and MutPred higher in 7. Of those papers, An openly licensed benchmark… ranks MutPred higher on its own (6 of 6).

Comparisons in which each paper scores MutFormer or MutPred higher2 other papers: MutFormer higher in 6, MutPred higher in 7, 0 ties.2 other papers6 MutFormer higher67 MutPred higher7
MutFormer higherTieMutPred higher
Compared
MutFormer, MutPred

Not reviewed yet.

MutFormer and phyloP: Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) and An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers disagree

  • Low severity
  • Not yet reviewed
  • Two-study conflict
  • unknown

Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) ranks MutFormer above phyloP in 7 of 7 comparisons; An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers ranks phyloP above MutFormer in 4 of 5 comparisons. No other study gives a verdict, so neither is the outlier.

2 papers rank MutFormer above phyloP in 8 of their 13 comparisons and phyloP higher in 4; 1 is a tie. Of those papers, An openly licensed benchmark… ranks phyloP higher on its own (4 of 6).

Comparisons in which each paper scores MutFormer or phyloP higher2 other papers: MutFormer higher in 8, phyloP higher in 4, 1 tie.2 other papers8 MutFormer higher81 tie4 phyloP higher4
MutFormer higherTiephyloP higher
Compared
MutFormer, phyloP

Not reviewed yet.

MutFormer and PrimateAI: Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) and An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers disagree

  • Low severity
  • Not yet reviewed
  • Two-study conflict
  • unknown

Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) ranks MutFormer above PrimateAI in 7 of 7 comparisons; An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers ranks PrimateAI above MutFormer in 6 of 6 comparisons. No other study gives a verdict, so neither is the outlier.

2 papers rank MutFormer above PrimateAI in 7 of their 13 comparisons and PrimateAI higher in 6. Of those papers, An openly licensed benchmark… ranks PrimateAI higher on its own (6 of 6).

Comparisons in which each paper scores MutFormer or PrimateAI higher2 other papers: MutFormer higher in 7, PrimateAI higher in 6, 0 ties.2 other papers7 MutFormer higher76 PrimateAI higher6
MutFormer higherTiePrimateAI higher
Compared
MutFormer, PrimateAI

Not reviewed yet.

Eigen and MutFormer: Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) and An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers disagree

  • Low severity
  • Not yet reviewed
  • Two-study conflict
  • unknown

Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) ranks MutFormer above Eigen in 7 of 7 comparisons; An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers ranks Eigen above MutFormer in 6 of 6 comparisons. No other study gives a verdict, so neither is the outlier.

2 papers rank Eigen above MutFormer in 6 of their 13 comparisons and MutFormer higher in 7. Of those papers, Livesey and Marsh 2025 ranks MutFormer higher on its own (7 of 7).

Comparisons in which each paper scores Eigen or MutFormer higher2 other papers: Eigen higher in 6, MutFormer higher in 7, 0 ties.2 other papers6 Eigen higher67 MutFormer higher7
Eigen higherTieMutFormer higher
Compared
Eigen, MutFormer

Not reviewed yet.

MutFormer and VEST4: Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) and An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers disagree

  • Low severity
  • Not yet reviewed
  • Two-study conflict
  • unknown

Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) ranks MutFormer above VEST4 in 6 of 7 comparisons; An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers ranks VEST4 above MutFormer in 6 of 6 comparisons. No other study gives a verdict, so neither is the outlier.

2 papers rank MutFormer above VEST4 in 6 of their 13 comparisons and VEST4 higher in 7. Of those papers, An openly licensed benchmark… ranks VEST4 higher on its own (6 of 6).

Comparisons in which each paper scores MutFormer or VEST4 higher2 other papers: MutFormer higher in 6, VEST4 higher in 7, 0 ties.2 other papers6 MutFormer higher67 VEST4 higher7
MutFormer higherTieVEST4 higher
Compared
MutFormer, VEST4

Not reviewed yet.

MutFormer and MutScore: Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) and An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers disagree

  • Low severity
  • Not yet reviewed
  • Two-study conflict
  • unknown

Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) ranks MutFormer above MutScore in 6 of 7 comparisons; An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers ranks MutScore above MutFormer in 6 of 6 comparisons. No other study gives a verdict, so neither is the outlier.

2 papers rank MutFormer above MutScore in 6 of their 13 comparisons and MutScore higher in 7. Of those papers, An openly licensed benchmark… ranks MutScore higher on its own (6 of 6).

Comparisons in which each paper scores MutFormer or MutScore higher2 other papers: MutFormer higher in 6, MutScore higher in 7, 0 ties.2 other papers6 MutFormer higher67 MutScore higher7
MutFormer higherTieMutScore higher
Compared
MutFormer, MutScore

Not reviewed yet.

CADD and MutFormer: Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) and An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers disagree

  • Low severity
  • Not yet reviewed
  • Two-study conflict
  • unknown

Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) ranks MutFormer above CADD in 7 of 7 comparisons; An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers ranks CADD above MutFormer in 6 of 6 comparisons. No other study gives a verdict, so neither is the outlier.

2 papers rank CADD above MutFormer in 6 of their 13 comparisons and MutFormer higher in 7. Of those papers, Livesey and Marsh 2025 ranks MutFormer higher on its own (7 of 7).

Comparisons in which each paper scores CADD or MutFormer higher2 other papers: CADD higher in 6, MutFormer higher in 7, 0 ties.2 other papers6 CADD higher67 MutFormer higher7
CADD higherTieMutFormer higher
Compared
CADD, MutFormer

Not reviewed yet.